{"id":61160,"date":"2026-03-24T20:08:53","date_gmt":"2026-03-24T12:08:53","guid":{"rendered":"https:\/\/flcube.com\/?p=61160"},"modified":"2026-03-24T20:08:55","modified_gmt":"2026-03-24T12:08:55","slug":"alphamab-oncology-doses-first-patient-in-phase-iii-kn026-study-bispecific-her2-antibody-targets-adjuvant-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61160","title":{"rendered":"Alphamab Oncology Doses First Patient in Phase III KN026 Study \u2013 Bispecific HER2 Antibody Targets Adjuvant Breast Cancer"},"content":{"rendered":"\n

Alphamab Oncology<\/strong> (HKG: 9966<\/a>) announced first patient dosing<\/strong> in a Phase III clinical study<\/strong> of KN026<\/strong>, a bispecific antibody (BsAb)<\/strong> co-developed with CSPC Pharmaceutical Group<\/strong> (HKG: 1093<\/a>), in combination with docetaxel (albumin-bound)<\/strong> and chemotherapy<\/strong> as adjuvant therapy for HER2-positive (HER2+) breast cancer (BC)<\/strong>. The 1,800-patient randomized trial<\/strong> compares KN026-based regimen vs. trastuzumab + pertuzumab standard of care<\/strong>, targeting invasive disease-free survival (iDFS)<\/strong> as primary endpoint.<\/p>\n\n\n\n

Phase III Study Design<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Design<\/strong><\/td>Randomized, controlled, open-label, multicenter<\/td><\/tr>
Treatment Arms<\/strong><\/td>KN026 + HB1801 (albumin-bound docetaxel) + chemotherapy vs. trastuzumab + pertuzumab + chemotherapy<\/td><\/tr>
Patient Population<\/strong><\/td>~1,800 patients<\/strong> with resectable HER2+ BC; \u22654 positive regional lymph nodes<\/strong> post-surgery<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Invasive disease-free survival (iDFS)<\/strong> \u2013 investigator-assessed<\/td><\/tr>
Secondary Endpoints<\/strong><\/td>DFS, RFI, DRFI, OS, safety, PK, immunogenicity<\/td><\/tr>
Phase<\/strong><\/td>Phase III (pivotal adjuvant trial)<\/td><\/tr>
Milestone<\/strong><\/td>First patient dosed (24\u202fMar\u202f2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

KN026 Product Profile<\/h2>\n\n\n\n
Attribute<\/th>KN026 Specification<\/th><\/tr><\/thead>
Format<\/strong><\/td>Bispecific antibody (BsAb)<\/strong> \u2013 dual HER2 epitope targeting<\/td><\/tr>
Epitopes<\/strong><\/td>Epitope II and IV<\/strong> (both clinically validated)<\/td><\/tr>
Fc Region<\/strong><\/td>Wild-type retained<\/strong> \u2013 enables ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity)<\/td><\/tr>
Positioning<\/strong><\/td>Global next-generation HER2-targeted therapy<\/strong> \u2013 enhanced efficacy via dual blockade + immune effector function<\/td><\/tr>
Development Partner<\/strong><\/td>CSPC Pharmaceutical Group<\/strong> (HKEX: 1093) \u2013 China rights for BC and gastric cancer (August 2021 agreement)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Partnership History<\/h2>\n\n\n\n
Date<\/th>Agreement<\/th><\/tr><\/thead>
August 2021<\/strong><\/td>Alphamab enters collaboration and licensing agreement<\/strong> with CSPC Pharma<\/td><\/tr>
Scope<\/strong><\/td>Development and commercialization of KN026 in mainland China<\/strong> for breast cancer and gastric cancer<\/strong><\/td><\/tr>
Financial Terms<\/strong><\/td>Not disclosed; typical milestone\/royalty structure for Phase II\/III assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Landscape<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
HER2+ Breast Cancer Market<\/strong><\/td>~20% of all breast cancers<\/strong>; adjuvant therapy standard (trastuzumab + pertuzumab + chemotherapy) reduces recurrence but 15\u201320% still relapse<\/strong> \u2013 unmet need for superior regimens<\/td><\/tr>
Bispecific HER2 Rationale<\/strong><\/td>Dual epitope blockade (II + IV) provides enhanced receptor clustering inhibition<\/strong> vs. trastuzumab (Epitope IV only) or pertuzumab (Epitope II only); wild-type Fc adds immune-mediated tumor killing<\/strong><\/td><\/tr>
KN026 Differentiation<\/strong><\/td>Only dual-epitope HER2 BsAb with wild-type Fc<\/strong> in Phase III; competitors (Zymeworks’ zanidatamab, Sutro’s STRO-002) have modified Fc or different epitope combinations<\/td><\/tr>
Adjuvant Setting Strategy<\/strong><\/td>High-risk population (\u22654 positive nodes) where recurrence risk justifies intensified therapy<\/strong>; success here supports broader adjuvant label<\/strong><\/td><\/tr>
Global Ambition<\/strong><\/td>Phase III design enables ex-China regulatory filings<\/strong> (FDA, EMA); Alphamab retains worldwide rights ex-China<\/strong> via CSPC China partnership structure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n